Nothing Special   »   [go: up one dir, main page]

KR20010014183A - 술폰아미드 화합물 및 그의 의약 용도 - Google Patents

술폰아미드 화합물 및 그의 의약 용도

Info

Publication number
KR20010014183A
KR20010014183A KR19997012258A KR19997012258A KR20010014183A KR 20010014183 A KR20010014183 A KR 20010014183A KR 19997012258 A KR19997012258 A KR 19997012258A KR 19997012258 A KR19997012258 A KR 19997012258A KR 20010014183 A KR20010014183 A KR 20010014183A
Authority
KR
South Korea
Prior art keywords
optionally substituted
sulfonamide compounds
alkylene
medicinal use
formula
Prior art date
Application number
KR19997012258A
Other languages
English (en)
Inventor
히로시 가야끼리
요시또 아베
히또시 하마시마
히또시 사와다
쯔요시 미즈따니
노리쯔구 야마사끼
오사무 오노무라
마사히로 니시까와
다까히로 히라무라
벤카트라가반 바수데반
데루오 오꾸
다까후미 이모또
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of KR20010014183A publication Critical patent/KR20010014183A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR19997012258A 1997-06-27 1998-06-24 술폰아미드 화합물 및 그의 의약 용도 KR20010014183A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20829597 1997-06-27
JP11471898 1998-04-24
PCT/JP1998/002877 WO1999000372A1 (en) 1997-06-27 1998-06-24 Sulfonamide compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
KR20010014183A true KR20010014183A (ko) 2001-02-26

Family

ID=26453401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR19997012258A KR20010014183A (ko) 1997-06-27 1998-06-24 술폰아미드 화합물 및 그의 의약 용도

Country Status (12)

Country Link
US (3) US6348474B1 (ko)
EP (1) EP0995742A4 (ko)
KR (1) KR20010014183A (ko)
CN (1) CN1268942A (ko)
AU (1) AU745081B2 (ko)
BR (1) BR9810456A (ko)
CA (1) CA2295239A1 (ko)
IL (1) IL133575A0 (ko)
RU (1) RU2199532C2 (ko)
TW (1) TW426666B (ko)
WO (1) WO1999000372A1 (ko)
ZA (1) ZA985618B (ko)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010014183A (ko) * 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
ATE413386T1 (de) * 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
CA2327397A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
EP1136492A4 (en) * 1998-12-04 2002-03-27 Fujisawa Pharmaceutical Co SULFAMIDE COMPOUNDS AND USES THEREOF AS MEDICAMENTS
US6869950B1 (en) 1998-12-24 2005-03-22 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
IL143802A0 (en) 1998-12-24 2002-04-21 Fujisawa Pharmaceutical Co Imidazole derivatives and pharmaceutical compositions containing the same
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP2004506009A (ja) * 2000-08-11 2004-02-26 ファイザー・インク インスリン抵抗性症候群の治療
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2005021537A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
CN1852905A (zh) * 2003-08-21 2006-10-25 Osi制药公司 具有n-取代的苯并咪唑基的c-kit抑制剂
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005058280A2 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
EP1708991B1 (en) * 2004-01-22 2007-10-17 Pfizer Limited Sulfonamide derivatives for the treatment of diseases
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
AU2005214137B2 (en) * 2004-02-18 2008-05-29 Astrazeneca Ab Compounds
WO2005082414A2 (en) * 2004-03-02 2005-09-09 Astellas Pharma Inc. Concomitant drugs of a sulfonamide and another therapeutic agent
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2560528A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
EP1756039B1 (en) * 2004-05-14 2012-10-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CA2583667A1 (en) * 2004-10-12 2006-04-27 Jasbir Singh Sulfonamide peri-substituted bicyclics for occlusive artery disease
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
MX2007004560A (es) * 2004-10-16 2007-06-08 Astrazeneca Ab Proceso para hacer compuestos de fenoxi benzamida.
JP2008521903A (ja) * 2004-12-01 2008-06-26 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド N置換されたベンズイミダゾリルC−kit阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての2−フェニル置換イミダゾール[4,5b]ピリジン/ピラジンおよびプリン誘導体
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
CA2614746C (en) * 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2027117A2 (en) * 2006-05-16 2009-02-25 Decode Genetics EHF Process for preparing 7-(acryloyl)-indoles
JP5193866B2 (ja) 2006-08-08 2013-05-08 あすか製薬株式会社 キナゾリン誘導体
JP5159630B2 (ja) * 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
RU2009121756A (ru) * 2006-12-21 2011-01-27 Астразенека Аб (Se) Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk)
BRPI0808422A2 (pt) * 2007-03-06 2015-06-23 Novartis Ag Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
DK2247580T3 (en) 2008-03-05 2015-10-05 Merck Patent Gmbh Quinoxalinone derivatives AS INSULINSEKRETIONSSTIMULATORER, METHODS FOR OBTAINING THEREOF AND USE THEREOF FOR THE TREATMENT OF DIABETES
EA201100097A1 (ru) * 2008-08-04 2011-10-31 Астразенека Аб Производные пиразоло[3,4]пиримидин-4-ила и их применения для лечения диабета и ожирения
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドPfizer Limited 化合物
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
WO2012007861A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
DK2669270T3 (en) * 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
WO2012105594A1 (ja) 2011-02-01 2012-08-09 協和発酵キリン株式会社 縮環複素環誘導体
MY159058A (en) * 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
EP3495366A1 (en) * 2011-07-15 2019-06-12 Shionogi & Co., Ltd Azabenzimidazole derivative having ampk-activating activity
JP2013028559A (ja) * 2011-07-28 2013-02-07 Nippon Light Metal Co Ltd 3−クロロ−4−メチル安息香酸イソプロピル及びその製造方法
JP5965484B2 (ja) 2012-07-27 2016-08-03 佐藤製薬株式会社 ジフルオロメチレン化合物
TW201410677A (zh) 2012-07-31 2014-03-16 Kyowa Hakko Kirin Co Ltd 縮環雜環化合物
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
TWI731317B (zh) * 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶(trk)抑制劑
KR102561692B1 (ko) 2014-12-18 2023-07-28 젠자임 코포레이션 트로포미오신-관련 키나제(trk) 억제제의 약제학적 제형
PE20180573A1 (es) * 2015-07-20 2018-04-04 Genzyme Corp Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
TW201831471A (zh) * 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
DE102017123282A1 (de) * 2017-10-06 2019-04-11 Henkel Ag & Co. Kgaa Hydrolyselabile Silylenolether von Riechstoffketonen oder -aldehyden
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤
CN114732816B (zh) * 2022-03-03 2023-08-15 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗肾癌药物中的用途
CN115154466B (zh) * 2022-06-06 2023-08-15 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗糖尿病肾病药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606753A (en) 1984-06-15 1986-08-19 Shell Oil Company 4-substituted-2-oxabicyclo[2.2.1]heptane ether herbicides
ES2039237T3 (es) * 1986-04-24 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Procedimiento para preparar nuevos compuestos de acido difosfonico.
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9020338D0 (en) * 1990-09-18 1990-10-31 Lilly Industries Ltd Pharmaceutical compounds
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
WO1993019067A1 (en) * 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine derivatives as angiotensin ii antagonists
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ATE165823T1 (de) 1993-06-22 1998-05-15 Knoll Ag Isochinolin-derivate mit therapeutischer wirkung
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
FR2733233B1 (fr) 1995-04-20 1997-05-30 Roussel Uclaf Nouveaux derives de quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
AU722514B2 (en) 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
JP2000511533A (ja) * 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗薬
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6242474B1 (en) * 1997-06-27 2001-06-05 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
KR20010014183A (ko) * 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
EP1136492A4 (en) * 1998-12-04 2002-03-27 Fujisawa Pharmaceutical Co SULFAMIDE COMPOUNDS AND USES THEREOF AS MEDICAMENTS

Also Published As

Publication number Publication date
US6348474B1 (en) 2002-02-19
US6911469B2 (en) 2005-06-28
EP0995742A4 (en) 2004-08-25
US20040180947A1 (en) 2004-09-16
US20020099212A1 (en) 2002-07-25
TW426666B (en) 2001-03-21
RU2199532C2 (ru) 2003-02-27
AU745081B2 (en) 2002-03-14
IL133575A0 (en) 2001-04-30
BR9810456A (pt) 2001-09-25
WO1999000372A1 (en) 1999-01-07
CN1268942A (zh) 2000-10-04
AU7934598A (en) 1999-01-19
ZA985618B (en) 1999-01-19
EP0995742A1 (en) 2000-04-26
CA2295239A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
KR20010014183A (ko) 술폰아미드 화합물 및 그의 의약 용도
ES2115163T3 (es) Procedimiento para inhibir la proliferacion de celulas de musculos lisos y la restinosis.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
DE69010139D1 (de) Haarkräftigungsmittel.
TR199700803T1 (xx) Trombin-inhibit�rleri olarak yeni dipeptidik amidinler.
TR200102800T2 (tr) Yeni bileşikler.
SE9504661D0 (sv) New compounds
SE9604786D0 (sv) New compounds
CA2312935A1 (en) Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0862068A3 (en) Plastic articles for medical use
DK0415456T3 (da) Xanthinforbindelser
EP0842661A3 (en) Atherosclerosis treatment
TR200101865T2 (tr) İmidazol bileşimleri ve onların tıbbi kullanımları.
EP0632036A3 (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
IT1269176B (it) Eterobicicli ad attivita' fungicida
DE69318238D1 (de) Benzopyran-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Zellenschutzmittel
EP0340754A3 (en) Monopersulfates of amino-(poly) percarboxylic acids
FI852806A0 (fi) 2-substituerade -1,3-propylidendifosfonatderivat och deras framstaellning.
TR200002580T2 (tr) Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
ITMI930469A1 (it) Composti polimetilipeperidinici contenenti gruppi silanici atti all'impiego come stabilizzanti per materiali organici
DK296389D0 (da) Farmaceutiske forbindelser
IT1237129B (it) Composti piperidin-triazinici atti all'impiego come stabilizzanti per materiali organici.
NO981393D0 (no) Guanidinoproteasehemmere
WO1992019613A3 (fr) Compositions therapeutiques a base de derives de 1,2-dithiole-3-thione
TR199701202T1 (xx) Yeni hidroksimik asit t�revleri.

Legal Events

Date Code Title Description
A201 Request for examination
G170 Re-publication after modification of scope of protection [patent]
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application